- Senate passes Drug Quality and Security Act
- ROUNDTABLE: Pharmacy’s future in sync with technology
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- Roxane Labs' generic prostate drug gets tentative approval from FDA
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
WOODCLIFF LAKE, N.J. — The Food and Drug Administration has approved a generic drug for depression made by Par Pharmaceutical Cos., the drug maker said Tuesday.
Par announced the approval of bupropion hydrochloride extended-release tablets in the 300-mg strength. The drug is a generic version of GlaxoSmithKline's Wellbutrin XL and is used to treat major depressive disorder. The company already markets the generic drug in the 150-mg strength.
In September 2012, the FDA asked companies making generic bupropion hydrochloride extended-release tablets to conduct studies in order to ensure that their versions were as effective as the branded version following reports of differences in efficacy between the branded drug and some generics. Par said it conducted a study demonstrating that its version was equivalent to GSK's.
Are you a nurse practitioner or physician's assistant? Join our Facebook group to get all the latest news dedicated to delivering healthcare services to patients in retail pharmacy clinics.